Form 4: Day One Biopharmaceuticals Executive Samuel Blackman Reports Stock Transactions

Day One Biopharmaceuticals' Head of R&D, Samuel Blackman, reported the acquisition of shares through RSU vesting and a subsequent sale to cover tax liabilities.

Summary

• Samuel Blackman, Head of R&D at Day One Biopharmaceuticals, filed a Form 4 detailing recent transactions in the company's stock.
• On November 15, 2024, Blackman acquired a total of 8,686 shares of common stock through the vesting of Restricted Stock Units (RSUs).
• These RSUs vested in three tranches: 1,187, 1,437, and 6,062 shares.
• On November 18, 2024, Blackman sold 2,206 shares at a weighted average price of $13.2102 per share to cover tax obligations related to the RSU vesting.
• Following these transactions, Blackman directly owns 1,064,015 shares of Day One Biopharmaceuticals common stock.
• Blackman also indirectly owns 1,000,000 shares through the 2021 Blackman Family LLC, where he shares voting and dispositive power with his wife.

Sentiment

Score: 7

Explanation: The document reflects routine insider transactions related to executive compensation. There is no indication of unusual activity or negative sentiment. The transactions are expected and do not suggest any significant change in the company's outlook.

Positives

• The vesting of RSUs indicates continued alignment of executive compensation with company performance.
• The sale of shares was explicitly for tax liability purposes, which is a common practice.

Industry Context

This filing is a routine disclosure of insider transactions, which is common in the pharmaceutical industry. It provides transparency into executive stock ownership and trading activity.

Comparison to Industry Standards

• Executive stock transactions are a common occurrence in publicly traded companies, particularly in the biotech sector.
• The use of RSUs as part of executive compensation is standard practice, aligning executive interests with shareholder value.
• The sale of shares to cover tax liabilities is a typical transaction following RSU vesting.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they are related to executive compensation and tax obligations.
• The sale of shares is unlikely to significantly affect the stock price.

Key Dates

Keywords

Form 4, insider trading, stock transaction, RSU, Day One Biopharmaceuticals, Samuel Blackman, executive compensation, share sale, vesting